109 related articles for article (PubMed ID: 2227540)
1. Adjuvant chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (PAC) for early-stage high-risk endometrial cancer: a preliminary analysis.
Stringer CA; Gershenson DM; Burke TW; Edwards CL; Gordon AN; Wharton JT
Gynecol Oncol; 1990 Sep; 38(3):305-8. PubMed ID: 2227540
[TBL] [Abstract][Full Text] [Related]
2. Postoperative adjuvant cisplatin, doxorubicin, and cyclophosphamide (PAC) chemotherapy in women with high-risk endometrial carcinoma.
Burke TW; Gershenson DM; Morris M; Stringer CA; Levenback C; Tortolero-Luna G; Baker VV
Gynecol Oncol; 1994 Oct; 55(1):47-50. PubMed ID: 7959265
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin, doxorubicin hydrochloride, and cyclophosphamide followed by radiotherapy in high-risk endometrial carcinoma.
Smith MR; Peters WA; Drescher CW
Am J Obstet Gynecol; 1994 Jun; 170(6):1677-81; discussion 1681-2. PubMed ID: 8203425
[TBL] [Abstract][Full Text] [Related]
4. Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC).
Levenback C; Burke TW; Silva E; Morris M; Gershenson DM; Kavanagh JJ; Wharton JT
Gynecol Oncol; 1992 Sep; 46(3):317-21. PubMed ID: 1526508
[TBL] [Abstract][Full Text] [Related]
5. Uterine papillary serous carcinoma treated with intraperitoneal cisplatin and intravenous doxorubicin and cyclophosphamide.
Chambers JT; Chambers SK; Kohorn EI; Carcangiu ML; Schwartz PE
Gynecol Oncol; 1996 Mar; 60(3):438-42. PubMed ID: 8774654
[TBL] [Abstract][Full Text] [Related]
6. Prospective treatment of advanced or recurrent endometrial carcinoma with cisplatin, doxorubicin, and cyclophosphamide.
Burke TW; Stringer CA; Morris M; Freedman RS; Gershenson DM; Kavanagh JJ; Edwards CL
Gynecol Oncol; 1991 Mar; 40(3):264-7. PubMed ID: 2013451
[TBL] [Abstract][Full Text] [Related]
7. Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma.
Sutton GP; Stehman FB; Einhorn LH; Roth LM; Blessing JA; Ehrlich CE
J Clin Oncol; 1989 Feb; 7(2):223-9. PubMed ID: 2915238
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant chemotherapy as treatment of high-risk stage I and II endometrial cancer.
Aoki Y; Watanabe M; Amikura T; Obata H; Sekine M; Yahata T; Fujita K; Tanaka K
Gynecol Oncol; 2004 Aug; 94(2):333-9. PubMed ID: 15297170
[TBL] [Abstract][Full Text] [Related]
9. Impact on progression-free survival of adjuvant cyclophosphamide, vincristine, doxorubicin (adriamycin), and dacarbazine (CYVADIC) chemotherapy for stage I uterine sarcoma. A prospective trial.
Hempling RE; Piver MS; Baker TR
Am J Clin Oncol; 1995 Aug; 18(4):282-6. PubMed ID: 7625366
[TBL] [Abstract][Full Text] [Related]
10. Preliminary analysis of RTOG 9708: Adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer.
Greven K; Winter K; Underhill K; Fontenesci J; Cooper J; Burke T;
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):168-73. PubMed ID: 15093913
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study.
Susumu N; Sagae S; Udagawa Y; Niwa K; Kuramoto H; Satoh S; Kudo R;
Gynecol Oncol; 2008 Jan; 108(1):226-33. PubMed ID: 17996926
[TBL] [Abstract][Full Text] [Related]
12. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma.
Shin DM; Fossella FV; Umsawasdi T; Murphy WK; Chasen MH; Walsh G; Komaki R; McMurtrey MJ; Hong WK
Cancer; 1995 Dec; 76(11):2230-6. PubMed ID: 8635025
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
[TBL] [Abstract][Full Text] [Related]
14. Treatment of advanced and recurrent endometrial cancer with cisplatin, doxorubicin, and cyclophosphamide.
Dunton CJ; Pfeifer SM; Braitman LE; Morgan MA; Carlson JA; Mikuta JJ
Gynecol Oncol; 1991 May; 41(2):113-6. PubMed ID: 2050302
[TBL] [Abstract][Full Text] [Related]
15. Two sequential studies for primary peritoneal carcinoma: induction with weekly cisplatin followed by either cisplatin-doxorubicin-cyclophosphamide or paclitaxel-cisplatin.
Piver MS; Eltabbakh GH; Hempling RE; Recio FO; Blumenson LE
Gynecol Oncol; 1997 Nov; 67(2):141-6. PubMed ID: 9367697
[TBL] [Abstract][Full Text] [Related]
16. [Adjuvant chemotherapy with cyclophosphamide, adriamycin, and CDDP (CAP) for high risk endometrial cancer after complete surgery].
Tsunoda H; Nishida M; Arisawa Y; Sato T; Oki A; Nishide K; Ichikawa Y; Kubo T
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Jan; 48(1):45-51. PubMed ID: 8576621
[TBL] [Abstract][Full Text] [Related]
17. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.
Conte PF; Bruzzone M; Chiara S; Sertoli MR; Daga MG; Rubagotti A; Conio A; Ruvolo M; Rosso R; Santi L
J Clin Oncol; 1986 Jun; 4(6):965-71. PubMed ID: 3519886
[TBL] [Abstract][Full Text] [Related]
18. Feasibility study of concurrent weekly cisplatin and whole abdominopelvic irradiation followed by doxorubicin/cisplatin chemotherapy for advanced stage endometrial carcinoma: a Gynecologic Oncology Group trial.
Soper JT; Reisinger SA; Ashbury R; Jones E; Clarke-Pearson DL
Gynecol Oncol; 2004 Oct; 95(1):95-100. PubMed ID: 15385116
[TBL] [Abstract][Full Text] [Related]
19. Intravenous cisplatin, doxorubicin, and cyclophosphamide in the treatment of uterine papillary serous carcinoma (UPSC).
Price FV; Chambers SK; Carcangiu ML; Kohorn EI; Schwartz PE; Chambers JT
Gynecol Oncol; 1993 Dec; 51(3):383-9. PubMed ID: 8112650
[TBL] [Abstract][Full Text] [Related]
20. Feasibility study of combination chemotherapy with paclitaxel, doxorubicin and cisplatin without prophylactic granulocyte colony-stimulating factor injection for intermediate-to-high risk or recurrent endometrial cancer.
Nagao S; Nishikawa T; Hanaoka T; Kurosaki A; Iwasa N; Hasegawa K; Fujiwara K
Jpn J Clin Oncol; 2014 Nov; 44(11):1040-4. PubMed ID: 25183770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
